• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受伏立康唑或卡泊芬净预防治疗的异基因造血干细胞移植受者中出现突破性播散性土曲霉感染。

Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.

作者信息

Pavie Juliette, Lacroix Claire, Hermoso Dea Garcia, Robin Marie, Ferry Christèle, Bergeron Anne, Feuilhade Martine, Dromer Françoise, Gluckman Eliane, Molina Jean-Michel, Ribaud Patricia

机构信息

Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis, Paris, France.

出版信息

J Clin Microbiol. 2005 Sep;43(9):4902-4. doi: 10.1128/JCM.43.9.4902-4904.2005.

DOI:10.1128/JCM.43.9.4902-4904.2005
PMID:16145172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1234079/
Abstract

Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.

摘要

ustus曲霉是一种临床少见的对抗真菌药物敏感性较差的菌种。我们报告了两例发生在异基因干细胞移植受者中的ustus曲霉感染病例，这些患者在接受伏立康唑或卡泊芬净治疗期间发病。长期使用这些新型抗真菌药物可能会增加耐药菌出现的风险。

相似文献

1
Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.接受伏立康唑或卡泊芬净预防治疗的异基因造血干细胞移植受者中出现突破性播散性土曲霉感染。
J Clin Microbiol. 2005 Sep;43(9):4902-4. doi: 10.1128/JCM.43.9.4902-4904.2005.
2
Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.接受卡泊芬净治疗的异基因造血干细胞移植受者发生突破性侵袭性曲霉病。
Int J Antimicrob Agents. 2007 Dec;30(6):551-4. doi: 10.1016/j.ijantimicag.2007.07.026.
3
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.伏立康唑与卡泊芬净联合作为实体器官移植受者侵袭性曲霉病的初始治疗：一项前瞻性、多中心、观察性研究。
Transplantation. 2006 Feb 15;81(3):320-6. doi: 10.1097/01.tp.0000202421.94822.f7.
4
Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft.一名自体干细胞移植原发性失败的患者，采用伏立康唑、卡泊芬净、粒细胞输注及手术联合治疗播散性曲霉病，随后进行异基因造血干细胞移植，治疗成功。
Eur J Haematol. 2005 May;74(5):438-41. doi: 10.1111/j.1600-0609.2004.00384.x.
5
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.移植患者侵袭性曲霉菌感染的抗真菌治疗与住院时间。
Med Mycol. 2013 Feb;51(2):128-35. doi: 10.3109/13693786.2012.690108. Epub 2012 Jun 11.
6
Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.肺移植受者侵袭性肺曲霉病采用伏立康唑和卡泊芬净联合治疗的临床转归。
J Clin Pharm Ther. 2010 Feb;35(1):49-53. doi: 10.1111/j.1365-2710.2009.01061.x.
7
Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.一名因慢性移植物抗宿主病接受免疫抑制治疗的患者，采用两性霉素B脂质复合物、卡泊芬净和伏立康唑联合治疗成功治愈合并肺毛霉菌病和曲霉病。
Bone Marrow Transplant. 2004 May;33(10):1065-6. doi: 10.1038/sj.bmt.1704485.
8
Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.接受伏立康唑预防治疗的异基因造血干细胞移植患者侵袭性曲霉病的发病率。
Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12. doi: 10.1016/j.diagmicrobio.2006.01.018. Epub 2006 Apr 19.
9
Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.卡泊芬净与伏立康唑联合用药在实验性曲霉病中的疗效。
Antimicrob Agents Chemother. 2005 Sep;49(9):3697-701. doi: 10.1128/AAC.49.9.3697-3701.2005.
10
Successful antifungal combination therapy with voriconazole and caspofungin.伏立康唑与卡泊芬净联合抗真菌治疗成功。
Pediatr Blood Cancer. 2005 Jun 15;44(7):682-5. doi: 10.1002/pbc.20302.

引用本文的文献

1
Fungal brain abscesses caused by species.由[具体物种]引起的真菌性脑脓肿。 （你提供的原文中“species”前缺少具体物种名称，翻译只能到此为止）
Egypt J Intern Med. 2023;35(1):5. doi: 10.1186/s43162-022-00183-z. Epub 2023 Jan 30.
2
Successful Treatment of Disseminated Disease Due to Highly Resistant Aspergillus calidoustus with a Novel Antifungal Therapy.新型抗真菌疗法成功治疗耐多药尖端赛多孢菌所致播散性疾病。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0220621. doi: 10.1128/aac.02206-21. Epub 2021 Dec 20.
3
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.异基因造血细胞移植受者中耐多药热黄曲霉导致侵袭性真菌感染的成功治疗。
Mycopathologia. 2020 Apr;185(2):399-403. doi: 10.1007/s11046-019-00423-x. Epub 2020 Jan 10.
4
Aspergillus pseudodeflectus: a new human pathogen in liver transplant patients.曲霉菌 pseudodeflectus：肝移植患者的新人类病原体。
BMC Infect Dis. 2018 Dec 12;18(1):648. doi: 10.1186/s12879-018-3527-5.
5
Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies.卡泊芬净治疗烟曲霉可导致几丁质合成的几丁质合成酶G依赖性上调及富含几丁质的微菌落形成。
Antimicrob Agents Chemother. 2015 Oct;59(10):5932-41. doi: 10.1128/AAC.00862-15. Epub 2015 Jul 13.
6
Update on Antifungal Drug Resistance.抗真菌药物耐药性的最新进展
Curr Clin Microbiol Rep. 2015 Jun 1;2(2):84-95. doi: 10.1007/s40588-015-0015-1.
7
Multi-resistant aspergillosis due to cryptic species.由隐匿菌种引起的多重耐药曲霉菌病
Mycopathologia. 2014 Dec;178(5-6):435-9. doi: 10.1007/s11046-014-9774-0. Epub 2014 Jun 27.
8
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.多中心研究伊曲康唑 MIC 分布和曲霉属的 CLSI M38-A2 肉汤微量稀释法的流行病学截断值。
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
9
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.CLSI 和 EUCAST 肉汤微量稀释法检测新型口服葡聚糖合成酶抑制剂（MK-3118）对曲霉菌属的体外活性。
Antimicrob Agents Chemother. 2013 Feb;57(2):1065-8. doi: 10.1128/AAC.01588-12. Epub 2012 Dec 10.
10
New taxa in Aspergillus section Usti.乌氏丛梗孢属中新分类单元。
Stud Mycol. 2011 Jun 30;69(1):81-97. doi: 10.3114/sim.2011.69.06.

本文引用的文献

1
Utility of Aspergillus antigen detection in specimens other than serum specimens.曲霉菌抗原检测在血清标本以外的其他标本中的应用。
Clin Infect Dis. 2004 Nov 15;39(10):1467-74. doi: 10.1086/425317. Epub 2004 Oct 26.
2
Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection.采用肺切除术和伏立康唑成功治疗侵袭性ustus肺曲霉感染。
J Clin Microbiol. 2004 Oct;42(10):4805-8. doi: 10.1128/JCM.42.10.4805-4808.2004.
3
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.接受伏立康唑预防治疗的造血干细胞移植受者中的侵袭性毛霉菌病
Clin Infect Dis. 2004 Aug 15;39(4):584-7. doi: 10.1086/422723. Epub 2004 Jul 30.
4
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.接受伏立康唑治疗的干细胞移植受者发生的突破性真菌感染。
Clin Infect Dis. 2004 Sep 1;39(5):743-6. doi: 10.1086/423274. Epub 2004 Aug 13.
5
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.造血干细胞移植受者伏立康唑治疗后发生的突破性接合菌病。
N Engl J Med. 2004 Feb 26;350(9):950-2. doi: 10.1056/NEJM200402263500923.
6
Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation.低强度干细胞移植后由ustus曲霉引起的原发性皮肤曲霉病。
Ann Hematol. 2002 Oct;81(10):593-6. doi: 10.1007/s00277-002-0511-2. Epub 2002 Sep 24.
7
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.异基因干细胞移植受者中的侵袭性曲霉病：流行病学和危险因素的变化
Blood. 2002 Dec 15;100(13):4358-66. doi: 10.1182/blood-2002-05-1496. Epub 2002 Aug 22.
8
Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.NCCLS M27-A和EUCAST肉汤微量稀释法对念珠菌属进行抗真菌药敏试验的比较评估。
Antimicrob Agents Chemother. 2002 Nov;46(11):3644-7. doi: 10.1128/AAC.46.11.3644-3647.2002.
9
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.伏立康唑与两性霉素B用于侵袭性曲霉病的初始治疗比较
N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191.
10
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.定义癌症和造血干细胞移植免疫受损患者中的机会性侵袭性真菌感染：一项国际共识。
Clin Infect Dis. 2002 Jan 1;34(1):7-14. doi: 10.1086/323335. Epub 2001 Nov 26.